DexCom (NASDAQ:DXCM) Shares Gap Up – Still a Buy?

Shares of DexCom, Inc. (NASDAQ:DXCM) gapped up before the market opened on Monday . The stock had previously closed at $77.76, but opened at $82.00. DexCom shares last traded at $78.42, with a volume of 540,973 shares traded.

Analysts Set New Price Targets

A number of brokerages have weighed in on DXCM. Citigroup lifted their price target on shares of DexCom from $85.00 to $91.00 and gave the company a “buy” rating in a research report on Wednesday, December 11th. Raymond James cut their target price on DexCom from $115.00 to $99.00 and set a “strong-buy” rating on the stock in a research report on Friday, October 25th. Canaccord Genuity Group upped their price target on DexCom from $89.00 to $99.00 and gave the stock a “buy” rating in a research note on Monday, December 9th. Leerink Partners dropped their price objective on DexCom from $90.00 to $87.00 and set an “outperform” rating for the company in a research note on Friday, October 25th. Finally, Wells Fargo & Company increased their target price on DexCom from $90.00 to $94.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 11th. Seven investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $98.00.

DexCom Trading Down 0.8 %

The firm has a market capitalization of $30.92 billion, a PE ratio of 47.41, a PEG ratio of 2.36 and a beta of 1.12. The company’s 50-day moving average price is $77.33 and its 200-day moving average price is $78.35. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.12 and a current ratio of 2.46.

Insider Transactions at DexCom

In other news, EVP Sadie Stern sold 4,259 shares of the firm’s stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total transaction of $318,275.07. Following the sale, the executive vice president now owns 71,192 shares of the company’s stock, valued at approximately $5,320,178.16. This trade represents a 5.64 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.30% of the company’s stock.

Hedge Funds Weigh In On DexCom

Hedge funds have recently added to or reduced their stakes in the stock. Versant Capital Management Inc purchased a new stake in shares of DexCom during the 4th quarter worth approximately $25,000. Riverview Trust Co raised its stake in DexCom by 100.4% during the 3rd quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock worth $31,000 after acquiring an additional 232 shares in the last quarter. RPg Family Wealth Advisory LLC purchased a new stake in DexCom in the third quarter valued at $57,000. Covestor Ltd boosted its stake in DexCom by 53.7% in the third quarter. Covestor Ltd now owns 959 shares of the medical device company’s stock valued at $64,000 after acquiring an additional 335 shares in the last quarter. Finally, Blue Trust Inc. grew its holdings in shares of DexCom by 101.9% during the third quarter. Blue Trust Inc. now owns 1,779 shares of the medical device company’s stock worth $119,000 after purchasing an additional 898 shares during the last quarter. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.